active pharmaceutical ingredients

How to identify the Complete Drug Patterns?

Pharmaceutical companies invest huge dollars in R & D , production and marketing of a newly developed drug . As law, the patent term is 20 years , ut it !s roughly "# to "$ years in the case of drug patents , as they have to pass %DA regulations , efore entering the markets. &hen the patent e'pires, generic companies come with the generic version of the same drug and selling in the market with a very low price . (herefore, to e competitive , innovative companies try to e'tend the lifetime of drugs. (his is known as the e'tent of the drug known to protect longer. (hat is why a specific drug is not protected y a patent in particular , ut is covered y various patents, including patents locking . Patents do not protect drugs as such, ut )inventions ) . A etter understanding of the different types of pharmaceutical patents and ways to e'tend the life of drug patents is essential for patent professionals involved in pharmaceutical research . Patent medicines can e classified into following categories* composition formulations Product form Drug release compound +ew chemical entity fitness Particle si,e selection patents (he active meta olites prodrugs Dose - dose .ethod or process (he use or application

Drug delivery devices "/ 0omposition 0omposition patent descri es a com ination of one or more of the 1 known or novel/, carriers or e'cipients and active ingredients such as solvents , uffers, fillers , inders, desintegrants , pharmaceutically accepta le lu ricants . (he inventiveness of these patents is on the selected com ination of molecules and their specific application new feature. lidocaine hydrochloride 2n 2ndia, a new pharmaceutical composition with a single active ingredient 1either known or novel/ with an inert carrier is not patenta le , since there is no synergy etween the components vi,. the active compound and the inert carrier. 2/ %ormulation A formulation patent relates to the preparation of the particular composition , in any particular desired shape for etter effect , form or release . 2."/ Product %orm* (his refers to the different dosage form of new or already known composition or pharmaceutical drug delivery method has the most active drug. (he active ingredient can e formulated in various forms , such as ta lets, capsules or a3ueous solutions for parenteral administration . %or e'ample, an anti4 inflammatory cream containing A can e regarded as distinctly different from a ta let containing the )A) for the control of dia etes . (he cream is new ecause )A) has never een formulated in this way efore, and e inventive if the previous use of )A) would not recommend using topically . )

2.2 / drug release * 2n some patents , the claimed formulation is associated with certain effects such as controlled release into the lood of a drug . 5ther drug delivery methods include timed e'tended and slow release .

6/ 0ompound (hese related to the identification of a new chemical , iological molecule , or her al patent medicines . (he patent may or may not say anything a out the composition 1 when aggregated with other ingredients/ , the application or use of such molecules . 2n most cases these new molecules are represented y different formulas in the claims 1 claims .arkush / . (hese compounds may e new molecules form some sources 1eg , iological , her al / or new chemical entity 1 +07/. (hey can e classified on the asis of the nature of the compound , ie , polymorph , isomer , 1 crystalline or amorphous / physical forms or salts . 8ocal Anesthetics

6."/ new chemical entity * A new chemical entity 1 +07 / is usually represented y .arkush structures in patent claims and reveals different chemical formulas and derivatives of new drugs. 6.2 / Physical %orm * Polymorphism and enantiomerism of chemicals property are e'ploited y pharmaceutical companies as the life cycle of drugs y novel polymorphs of the invention, isomers, physical forms 1crystalline or amorphous / , enantiomers of drug know . 6.6 / Particle si,e* (he dissolution rate of a drug is a function of its intrinsic solu ility and particle si,e. Reduction of particle si,e can lead to increased dissolution rate and higher ioavaila ility , therefore a large num er of patents in the pharmaceutical industries related to the composition to specific particle si,e of the ingredients along with dosage forms 1 for e'ample , suspensions or dispersions / . 6.9/ selection patents * 2n a ! selection patent )says a single item or a small segment within a larger group known is ! selected! and independently claimed ased on a particular feature not mentioned in the large group . for e'ample , a patent on a specific range 1eg , 06 4 0"2 / states if a chemical having n car on atoms is already patented . 6.:/ active meta olites * 2n some cases , patents are focused on a compound and the active meta olite that produces the desired effect in the ody . (he same effect than the parent drug compound is produced . 6.# / Prodrugs * when meta oli,ed in the ody inactive compounds 1called ) prodrugs ) / may produce a therapeutically active ingredient . ;ome patent claims cover a drug and prodrug - s . 9/ Dose - dose ;ome patent documents claim inventions that consist of the dosage form for administration 1e.g., solid dosage form for oral administration / to patients of an e'isting product. (hese claims are usually coincides with claims on methods for medical treatment , and that matter is not a product or process, ut the way a product is used therapeutically . : / (he method or process (hese patents disclose the method or process for the manufacture or preparation , either a compound or composition. (hey will in most cases also disclose the application of said compound or composition . 5ther patents in this category is the method of identifying novel molecules , methods of treatment , screening or diagnostic method . (hese patents also include different methods of testing. #/ (he use or application (he focus of such patents is the effect of the compound or composition in a human ody or other issues, such as treatment and prevention of specific diseases/ </ Delivery of drugs

(hese patents give su stantive information or any method or device or system for the delivery of drugs into the human ody . 2ncludes oth the administration of drugs in general and the drug delivery system or method . </ Devices 2ncludes patents that descri e any device, apparatus, e3uipment or system sometimes for drug delivery, manufacturing , surveillance , detection or diagnosis of particular drug and its activity . 0onclusion 2t is a myth among analyst Pat , reading and understanding of the patent is resistant carpet . (rue, ut if you have a clear understanding of the different types of patents, drug formulations and asic terminology used in pharmaceutical patents , which will make life easy. A careful reading of patent applications to identify the novelty and inventive step , along with the title and the summary can provide high4level information a out a patent . .ahendra 0hemicals is an =; %DA approved 2;5 >00"*200$ certified 8idocaine Drug and pharmaceutical manufacturer.